Molnlycke Health Care Introduces Biogel PI Pro-Fit
Mölnlycke Health Care US, LLC introduces Biogel PI Pro-Fit®, a non-latex surgical glove designed to allow for a new level of comfort during surgery while reducing employee and patient health risks and costs.
Designed with a biomechanically optimized former to help prevent hand fatigue during surgery and a synthetic material that feels just as good as latex, 94 percent of surgeons surveyed rated Biogel PI (non-latex) as good as or better than Biogel Latex.
According to a recent study, there are approximately 17 operating room (OR) backtable teardowns per year on average per facility due to undetected latex allergies in patients. With Biogel PI Pro-Fit®, the OR teardown cost risk associated with glove-related patient latex allergies is eliminated.
Additionally over time, healthcare workers can develop latex sensitivity, which can average costs up to $218,000 per employee to treat their latex allergy. Biogel non-latex gloves reduce the risk of workers compensation claims and lost productivity due to staff with glove-related latex allergies being unable to work.
Biogel gloves have statistically significant fewer observed failures than other glove brands, reducing the exposure to pathogens and associated costs of treatment. In an independent observational in-use comparison study, non-Biogel gloves were 3.5 times as likely to fail in-use compared to Biogel surgical gloves.
Source: Mölnlycke Health Care US, LLC Â
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
